Antibody Drug Conjugate Market (By Application: Blood Cancer [Leukemia, Lymphoma], Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor; By End-user: Hospitals, Clinics, ASC, Homecare, Others; By Technology: Cleavable Linker, Non-cleavable Linker) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 160

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
       1.1.1. Definition of Antibody Drug Conjugate
       1.1.2. Market Segmentation
       1.1.3. List of Abbreviations
1.2. Summary
       1.2.1. Market Snapshot
       1.2.2. Antibody Drug Conjugate Market By Application
                 1.2.2.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By Application (2015-2026)
                 1.2.2.2. Global Antibody Drug Conjugate Market Revenue Share By Application in 2017
                 1.2.2.3. Blood Cancer
                 1.2.2.4. Breast Cancer
                 1.2.2.5. Ovarian Cancer
                 1.2.2.6. Lung Cancer
                 1.2.2.7. Brain Tumor
                 1.2.2.8. Others
       1.2.3. Antibody Drug Conjugate Market By End-user
                 1.2.3.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By End-user (2015-2026)
                 1.2.3.2. Hospitals
                 1.2.3.3. Clinics
                 1.2.3.4. ASC
                 1.2.3.5. Homecare
                 1.2.3.6. Others
       1.2.4. Antibody Drug Conjugate Market By Technology
                 1.2.4.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By Technology (2015-2026)
                 1.2.4.2. Cleavable Linker
                 1.2.4.3. Non-cleavable Linker
                 1.2.4.4. Others
       1.2.5. Antibody Drug Conjugate Market by Geography
                 1.2.5.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison by Geography (2015-2026)
                 1.2.5.2. North America Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
                 1.2.5.3. Europe Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
                 1.2.5.4. Asia-Pacific Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
                 1.2.5.5. Latin America Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
                 1.2.5.6. Middle East and Africa (MEA) Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
       2.4.1. Bargaining Power of Suppliers
       2.4.2. Bargaining Power of Buyers
       2.4.3. Threat of Substitute
       2.4.4. Threat of New Entrants
       2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
       2.6.1. Raw Material and Suppliers
       2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
       2.8.1. Player Positioning Analysis
       2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antibody Drug Conjugate Major Manufacturers in 2017

CHAPTER 4. ANTIBODY DRUG CONJUGATE MARKET BY APPLICATION

4.1. Global Antibody Drug Conjugate Revenue By Application
4.2. Blood Cancer
       4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Breast Cancer
       4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Ovarian Cancer
       4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Lung Cancer
       4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Brain Tumor
       4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Other
       4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTIBODY DRUG CONJUGATE MARKET BY END-USER

5.1. Global Antibody Drug Conjugate Revenue By End-user
5.2. Hospitals
       5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Clinics
       5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. ASC
       5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Homecare
       5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Others
       5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTIBODY DRUG CONJUGATE MARKET BY TECHNOLOGY

6.1. Global Antibody Drug Conjugate Revenue By Technology
6.2. Cleavable Linker
       6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Non-cleavable Linker
       6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Others
       6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

7.1. North America Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
       7.3.1. U.S. Antibody Drug Conjugate Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       7.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       7.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.4. Canada
       7.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       7.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       7.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.5. Mexico
       7.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       7.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       7.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

8.1. Europe Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
       8.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       8.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       8.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.4. Germany
       8.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       8.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       8.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.5. France
       8.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       8.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       8.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.6. Spain
       8.6.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       8.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       8.6.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.7. Rest of Europe
       8.7.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       8.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       8.7.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

9.1. Asia-Pacific Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
       9.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       9.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       9.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4. Japan
       9.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       9.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       9.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.5. India
       9.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       9.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       9.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.6. Australia
       9.6.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       9.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       9.6.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.7. South Korea
       9.7.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       9.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       9.7.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
       9.8.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
       9.8.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
       9.8.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

10.1. Latin America Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
         10.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         10.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         10.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4. Argentina
         10.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         10.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         10.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5. Rest of Latin America
         10.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         10.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         10.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

11.1. Middle East Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
         11.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         11.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         11.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4. UAE
         11.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         11.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         11.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5. Rest of Middle East
         11.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         11.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         11.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

12.1. Africa Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
         12.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         12.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         12.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4. Egypt
         12.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         12.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         12.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5. Rest of Africa
         12.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
         12.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
         12.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. AbbVie Inc.
         13.1.1. Company Snapshot
         13.1.2. Overview
         13.1.3. Financial Overview
         13.1.4. Type Portfolio
         13.1.5. Key Developments
         13.1.6. Strategies
13.2. Seattle Genetics, Inc.
         13.2.1. Company Snapshot
         13.2.2. Overview
         13.2.3. Financial Overview
         13.2.4. Type Portfolio
         13.2.5. Key Developments
         13.2.6. Strategies
13.3. F. Hoffmann-La Roche Ltd.
         13.3.1. Company Snapshot
         13.3.2. Overview
         13.3.3. Financial Overview
         13.3.4. Type Portfolio
         13.3.5. Key Developments
         13.3.6. Strategies
13.4. Takeda Pharmaceutical Company Limited
         13.4.1. Company Snapshot
         13.4.2. Overview
         13.4.3. Financial Overview
         13.4.4. Type Portfolio
         13.4.5. Key Developments
         13.4.6. Strategies
13.5. Pfizer Inc.
         13.5.1. Company Snapshot
         13.5.2. Overview
         13.5.3. Financial Overview
         13.5.4. Type Portfolio
         13.5.5. Key Developments
         13.5.6. Strategies
13.6. Others
         13.6.1. Company Snapshot
         13.6.2. Overview
         13.6.3. Financial Overview
         13.6.4. Type Portfolio
         13.6.5. Key Developments
         13.6.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
         14.1.1. Initial Data Search
         14.1.2. Secondary Research
         14.1.3. Primary Research
14.2. Assumptions and Scope


Cart Summary